At Phenomic we leverage advanced machine learning tools to target the tumor stroma, a key barrier to today's medicines.
Phenomic is an early-stage biotech company based out of Toronto, targeting disease micro-environments in cancer and fibrosis. By using a combination of automated microscopy, single-cell sequencing, and machine learning Phenomic is able to screen targets in complex experimental models that better mimic the tumor microenvironment. Phenomic has also developed tools that let them map results back to human data, to ensure model relevance at the molecular level; a key challenge facing today's pipelines. To date, we've used this platform to identify key targets in the tumor stroma, for our lead indication colorectal cancer. We're now working to commercialize these targets and push them into pre-clinical studies.
Total Funding: $ 2M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2017
